Organ allocation for patients with acute-on-chronic liver failure: Time to look beyond MELD-sodium?
- PMID: 32703585
- DOI: 10.1016/j.jhep.2020.06.030
Organ allocation for patients with acute-on-chronic liver failure: Time to look beyond MELD-sodium?
Conflict of interest statement
Conflict of interest R.J. is an advisory board member for Takeda, Yaqrit and Mallinckrodt; has received research funding from Yaqrit and Takeda; owns stocks and shares in Yaqrit, Cyberliver and is an inventor of CARBALIVE; DIALIVE; Ornithine Phenylacetate and TLR4 antagonist. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure.J Hepatol. 2020 Dec;73(6):1425-1433. doi: 10.1016/j.jhep.2020.06.005. Epub 2020 Jun 10. J Hepatol. 2020. PMID: 32531416 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
